| abstract |
Disclosed is the use of therapeutically effective amount (preferably from 25 to 200 mg per day) of diacerein or a pharmaceutically acceptable salt thereof, monoacetylrhein or rhein, for preparing a medicament for treating type II diabetes mellitus in a subject with type II diabetes who has an inadequate response to an antidiabetic agent and whose hemoglobin A1c value is above 7%. The disclosure also relates to the use if a combination of (a) a therapeutically effective amount of diacerein, or a pharmaceutically acceptable salt thereof, monoacetylrhein or rhein, and (b) an antidiabetic agent selected from the group consisting of sulfonylurea, a biguanide, an alpha-glucosidase inhibitor, a thiazolidinedione, a peroxisome proliferator-activated receptor agonist, a dipeptidyl peptidase-4 inhibitor, a nonsulfonylurea insulin secretagogue, a glucagon-like petide-1 analog and insulin, for preparing a medicament for improving glycemic control in a subject with type II diabetes mellitus receiving at least one antidiabetic agent and whose hemoglobin A1c value is above 7%. |